AstraZeneca thyroid cancer drug gets EU approval

By Admin
UK pharmaceutical manufacturer AstraZeneca has been given a boost by European drug regulators who have approved its vandetanib drug as a potential trea...

UK pharmaceutical manufacturer AstraZeneca has been given a boost by European drug regulators who have approved its vandetanib drug as a potential treatment for thyroid cancer.

Vandetanib, also sold and marketed under the brand name Caprelsa, has a turbulent past few years and AstraZeneca will no doubt breathe a sigh of relief at its approval.

The drug will treat medullary thyroid cancer (MTC) tumours which are not suitable for surgical removal and have spread to other areas of the body.

To read the latest edition of Healthcare Global, click here

Approval of the drug came after the regulators reviewed the Phase III clinical trial data, which revealed using Caprelsa reduces the risk of the disease progressing by 54 percent by preventing blood from flowing to tumours and inhibiting their growth.  

At the moment there are no approved treatments for MTC in Europe.

When Caprelsa first emerged on the pharmaceutical scene it was tipped to be a blockbuster drug and was estimated to be worth $1billion to the company.

However, the drug hit a stumbling block when, in clinical trials, it was unable to extend the lives of cancer sufferers.

Pharmaceutical industry experts are now predicting the drug will not prove to be a blockbuster for AstraZenca, as it is targeted at a niche market as MTC affects only four percent of thyroid cancer sufferers.

Forecasts published on Thomson Reuters Pharma have estimated in five years time, by 2016, sales of Caprelsa will reach $112million, a far cry from its original £1billion estimations.

Our magazine is now available on the iPad. Click here to download it.

Share

Featured Articles

Siemens: smart finance to help medical technology growth

Penny Pinnock, Business Development Manager at Siemens Financial Services UK, discusses how adopting digital technology can support the healthcare sector

Healthcare Digital news roundup: prostate cancer & AI

This week in Healthcare Digital, we heard from experts in the sector: Trevor Dearing from Illumio, Avenda Health’s Brit Berry-Pusey & Vish Charan of Abbott

Lexica shares post-COVID-19 digital healthcare trends

Joanna Smith, Digital Advisory Lead at consulting company Lexica, explores the impact of COVID-19 on digital healthcare & what role health data can play

Medical devices expanding senior healthcare innovation

Medical Devices & Pharma

Abbott’s CRM medical devices can help cardiac arrhythmia

Medical Devices & Pharma

AutoRABIT CEO Meredith Bell on DevOps strategy in healthcare

Hospitals